| Form | Liquid |
|---|---|
| Host Species | Humanized |
| Clonality | Monoclonal |
| Isotype | IgG1, kappa |
| Purity | >95% purity as determined by SDS-PAGE. |
| Purification | Protein A/G purified from cell culture supernatant. |
| Concentration | 1mg/ml |
| Endotoxin Level | Please contact the lab for this information. |
| Applications | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
| Species Reactivity | Human immunodeficiency virus 1 (HIV-1) |
| Target | env/Env polyprotein |
| Storage Buffer | 0.01M PBS, pH 7.4. |
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
| Expression System | Mammalian Cells |
| Accession Number | P03377 |
| Background | Suvizumab (KD-247) is an neutralizing antibody anti-HIV-1. Suvizumab effectively neutralizes HIV-1MN, HIV-1SF2 and HIV-189.6 with IC50 values of 0.1 µg/mL, 1.0 µg/mL and 0.2 µg/mL, respectively. Suvizumab reduces the viral load of HIV. Suvizumab has good tolerance and can be used to prevent HIV infection. • Targeted infection of HIV-1 Env expressing cells by HIV(CD4/CXCR4) vectors reveals a potential new rationale for HIV-1 mediated down-modulation of CD4., PMID:16371160 • The intracytoplasmic domain of the Env transmembrane protein is a locus for attenuation of simian immunodeficiency virus SIVmac in rhesus macaques., PMID:10846063 • Differences in feline immunodeficiency virus host cell range correlate with envelope fusogenic properties., PMID:7856093 • Incomplete protection, but suppression of virus burden, elicited by subunit simian immunodeficiency virus vaccines., PMID:8107246 • Mechanistic analysis of pause site-dependent and -independent recombinogenic strand transfer from structurally diverse regions of the HIV genome., PMID:15342633 |
| Alternative Names | KD-247, 914257-21-9 |
| Note | For research use only. Not suitable for clinical or therapeutic use. |